Paper34638457
Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic.
Kumar S and 2 others. Cancers (Basel), 2021. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic. Papers, record 34638457. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34638457
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References168
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23238854 | Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. | Endocr Rev | 2013 | https://conductscience.org/library/papers/23238854 | PubMed |
| 2 | 30557851 | Non-canonical AR activity facilitates endocrine resistance in breast cancer. | Endocr Relat Cancer | 2019 | https://conductscience.org/library/papers/30557851 | PubMed |
| 3 | 16604168 | The cell-specific activity of the estrogen receptor alpha may be fine-tuned by phosphorylation-induced structural gymnastics. | Nucl Recept Signal | 2006 | https://conductscience.org/library/papers/16604168 | PubMed |
| 4 | 29899353 | A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes. | Nat Commun | 2018 | https://conductscience.org/library/papers/29899353 | PubMed |
| 5 | 26122181 | ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. | Nat Rev Clin Oncol | 2015 | https://conductscience.org/library/papers/26122181 | PubMed |
| 6 | 29514843 | The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29514843 | PubMed |
| 7 | 27885264 | Deciphering the divergent roles of progestogens in breast cancer. | Nat Rev Cancer | 2017 | https://conductscience.org/library/papers/27885264 | PubMed |
| 8 | 6216931 | Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies. | Breast Cancer Res Treat | 1981 | https://conductscience.org/library/papers/6216931 | PubMed |
| 9 | 26169690 | DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. | Nat Commun | 2015 | https://conductscience.org/library/papers/26169690 | PubMed |
| 10 | 24451109 | Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. | Breast Cancer Res | 2014 | https://conductscience.org/library/papers/24451109 | PubMed |
| 11 | 31353221 | Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. | Cell | 2019 | https://conductscience.org/library/papers/31353221 | PubMed |
| 12 | 24016618 | Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/24016618 | PubMed |
| 13 | 18071186 | Vitamin D intake and breast cancer risk in postmenopausal women. | Arch Intern Med | 2007 | https://conductscience.org/library/papers/18071186 | PubMed |
| 14 | 3975652 | Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. | Semin Oncol | 1985 | https://conductscience.org/library/papers/3975652 | PubMed |
| 15 | 31474332 | Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. | Lancet | 2019 | https://conductscience.org/library/papers/31474332 | PubMed |
| 16 | 21559012 | A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. | Br J Cancer | 2011 | https://conductscience.org/library/papers/21559012 | PubMed |
| 17 | 6225476 | Current status of high dose progestin treatment in advanced breast cancer. | Breast Cancer Res Treat | 1983 | https://conductscience.org/library/papers/6225476 | PubMed |
| 18 | 29991605 | Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. | Cancer Discov | 2018 | https://conductscience.org/library/papers/29991605 | PubMed |
| 19 | 14745018 | Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. | Proc Natl Acad Sci U S A | 2004 | https://conductscience.org/library/papers/14745018 | PubMed |
| 20 | 24480385 | Retinoids and breast cancer: from basic studies to the clinic and back again. | Cancer Treat Rev | 2014 | https://conductscience.org/library/papers/24480385 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38973256 | Double Imprinted Nanoparticles for Sequential Membrane-to-Nuclear Drug Delivery. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/38973256 | PubMed |
| 38717954 | Transcriptomic analysis revealed potential regulatory biomarkers and repurposable drugs for breast cancer treatment. | Cancer Rep (Hoboken) | 2024 | https://conductscience.org/library/papers/38717954 | PubMed |
| 38124194 | Addition of progesterone to feminizing gender-affirming hormone therapy in transgender individuals for breast development: a randomized controlled trial. | BMC Pharmacol Toxicol | 2023 | https://conductscience.org/library/papers/38124194 | PubMed |
| 37019926 | Impaired retinoic acid signaling in cerebral cavernous malformations. | Sci Rep | 2023 | https://conductscience.org/library/papers/37019926 | PubMed |
| 36661673 | The Role of Glucocorticoids in Breast Cancer Therapy. | Curr Oncol | 2022 | https://conductscience.org/library/papers/36661673 | PubMed |
| 35761157 | Mechanisms behind context-dependent role of glucocorticoids in breast cancer progression. | Cancer Metastasis Rev | 2022 | https://conductscience.org/library/papers/35761157 | PubMed |
| 35626007 | Nuclear Receptor Coregulators in Hormone-Dependent Cancers. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35626007 | PubMed |
| 35450488 | Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer. | Technol Cancer Res Treat | 2022 | https://conductscience.org/library/papers/35450488 | PubMed |
Genes29
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34638457
GET https://conductscience.org/api/papers/v1/34638457/references?page=2